Loading...
•
Dec 31, 2019
Capricor Q4 2019 Earnings Report
Announced financial results for the fourth quarter and full year 2019 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $1.5 million, or $0.34 per share, for the fourth quarter of 2019, compared to a net loss of $3.3 million, or $1.05 per share, for the fourth quarter of 2018. As of December 31, 2019, the Company’s cash, cash equivalents and marketable securities totaled approximately $9.9 million.
Made progress toward bringing CAP-1002 to patients with DMD, with final 12-month data expected in the second quarter.
Expanded exosomes technology to develop a platform of exosomal-based vaccines, potentially beneficial in indications like the novel coronavirus (SARS-CoV-2).
Strengthened exosomes program with the appointment of Dr. Stephen Gould.
Extended runway through the second quarter of 2021 due to recent financing and continues to pursue strategic partnerships.
Forward Guidance
Capricor expects 2020 to be a transformative year with clarity on next steps in its DMD program and the planned expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases, among other things.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...